This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Blueprint Medicines マネジメント
マネジメント 基準チェック /24
Blueprint Medicinesの CEO はKate Havilandで、 Apr2022年に任命され、 の在任期間は 3.25年です。 の年間総報酬は$ 13.48Mで、 6.1%給与と93.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.11%を直接所有しており、その価値は$ 9.14M 。経営陣と取締役会の平均在任期間はそれぞれ5年と10.2年です。
主要情報
Kate Haviland
最高経営責任者
US$13.5m
報酬総額
| CEO給与比率 | 6.09% |
| CEO在任期間 | 3.3yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 5yrs |
| 取締役会の平均在任期間 | 10.2yrs |
経営陣の近況
Recent updates
Seeking Alpha • Jun 18
Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade
Summary Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned $150m last quarter, and could reach $2bn in revenues by 2030. There are contingent value rights that may pay up to $6 per share based on a pipeline drug, BLU-808, achieving certain milestones. Sanofi had the money and the desire to do the deal, and the price paid will likely satisfy Bluerprint shareholders - up >600% since IPO. This is, therefore, a good deal for Sanofi, and Blueprint, and could kick off a bull run on stock, as Aykavit will be immediately revenue accretive. Read the full article on Seeking Alpha
新しいナラティブ • May 26
Expanding Patient Reach And Pipeline Development Will Unlock Potential
Strong AYVAKIT demand, expanded market reach, and improved therapy duration fuel revenue growth and enhance operating margin stability.Seeking Alpha • Mar 29
Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock
Summary Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to reach $2 billion in annual revenues by 2030, with significant growth potential as only 10% of the diagnosed SM market is penetrated. Blueprint is developing next-generation drugs like elenestinib and BLU-808, which could further enhance its SM franchise and diversify its revenue streams. Despite impressive growth and a strong cash position, I recommend a "hold" due to the stock's high valuation and the need for pipeline drugs to be further derisked. Read the full article on Seeking AlphaSeeking Alpha • Sep 27
Blueprint Medicines: Growth For The Long Term Still Mostly Priced In
Summary Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging net product revenue at $435-$450 million, a ~117% increase from 2023. CEO Haviland highlights AYVAKIT's multibillion-dollar potential, driven by its unique value proposition and strong adoption among physicians, patients, and payers. Blueprint's revised revenue guidance is based on strong first-half 2024 performance and growing experience with factors driving its business, particularly in systemic mastocytosis treatment. Read the full article on Seeking AlphaSeeking Alpha • Jul 16
Blueprint Medicines: Overdue For A Breather
Summary Today, we take a look at Blueprint Medicines Corporation, a company focused on developing precision therapies for cancers and blood disorders. Blueprint's Q1 results were spectacular, and the company has a solid balance sheet, but the stock is up more than 150% from its lows in late October. Can the shares rally further, or are they overdue for a breather? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 04
Blueprint Medicines: Rampant Growth Mostly Priced In
Summary Blueprint Medicines generates growing revenues from its FDA-approved product AYVAKIT/AYVAKYT. AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 2024 earnings, achieving $92.5 million in AYVAKIT net product revenues and raising guidance for full-year revenues. Read the full article on Seeking AlphaSeeking Alpha • Feb 20
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Summary Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn rate. Market sentiment is robust, supported by strong analyst projections, institutional interest, and stock momentum. I am upgrading my rating to a "strong buy," considering Ayvakit's market potential, financial health, and Blueprint's strategic positioning despite biotech investment risks. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$156m |
| Dec 31 2024 | US$13m | US$821k | -US$67m |
| Sep 30 2024 | n/a | n/a | -US$128m |
| Jun 30 2024 | n/a | n/a | -US$205m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
報酬と市場: Kateの 総報酬 ($USD 13.48M ) は、 US市場 ($USD 8.38M ) の同規模の企業の平均を上回っています。
報酬と収益: Kateの報酬は増加しましたが、会社は利益を上げていません。
CEO
Kate Haviland (49 yo)
3.3yrs
在職期間
US$13,477,004
報酬
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | no data | US$549.69k | 0.11% $ 9.6m | |
| Chief Financial Officer | 9.4yrs | US$4.19m | 0.067% $ 5.6m | |
| Chief Operating Officer | 3.3yrs | US$6.54m | 0.032% $ 2.7m | |
| Chief Scientific Officer | 4.2yrs | US$5.13m | 0.082% $ 6.9m | |
| President of Research & Development | 4.8yrs | US$5.50m | 0.049% $ 4.1m | |
| Senior Vice President of Finance and Principal Accounting Officer | no data | データなし | 0.026% $ 2.2m | |
| Senior Director & Head of Investor Relations | no data | データなし | データなし | |
| Executive VP | 8.8yrs | US$2.34m | 0.057% $ 4.8m | |
| Chief People Officer | 5.4yrs | データなし | 0.035% $ 3.0m | |
| Senior Vice President of Corporate Affairs | no data | データなし | データなし | |
| Chief Medical Officer | 5.2yrs | データなし | 0.047% $ 3.9m |
5.0yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: BPMCの経営陣は経験豊富で経験豊富です（平均在職期間は5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | 14.3yrs | US$549.69k | 0.11% $ 9.6m | |
| Chair of Scientific Advisory Board | 13.2yrs | US$333.38k | データなし | |
| Lead Independent Director | 9.3yrs | US$606.19k | 0.020% $ 1.7m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board & Independent Director | 14.3yrs | US$569.69k | 0.086% $ 7.2m | |
| Independent Director | 9.4yrs | US$572.59k | 0.0035% $ 289.6k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 3.6yrs | US$574.69k | 0.017% $ 1.4m | |
| Chairman of the Board of Director | 11yrs | US$586.19k | 0.22% $ 18.7m |
10.2yrs
平均在職期間
63yo
平均年齢
経験豊富なボード: BPMCの 取締役会 は経験豊富で 経験豊富 です ( 10.2年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2025/07/17 07:06 |
| 終値 | 2025/07/17 00:00 |
| 収益 | 2025/03/31 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Blueprint Medicines Corporation 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| George Farmer | BMO Capital Markets Equity Research |
| Dane Leone | BTIG |
| Arlinda Lee | Canaccord Genuity |